Indeed, decreased serum VIP and PACAP levels have been detected in human blood and cerebrospinal fluid (CSF) samples, respectively [23,24], suggesting that these neuropeptides may also find application as biomarkers of disease and/or be utilized to monitor MS progression. The gene discussed is VIP; the disease is myeloid sarcoma.